Navigation path

Community Register of medicinal products

Community register of orphan medicinal products


GRANTED  

Product information

Sorafenib tosylate

EU orphan designation number: EU/3/04/207   
Active ingredient: Sorafenib tosylate
Indication: Treatment of renal cell carcinoma
Sponsor: Bayer Schering Pharma AG
D-13342 Berlin, Deutschland
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Nexavar on 19/07/2006 with the number EU/1/06/342

   Public summary of scientific opinion     EPAR

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
02/08/2004 Centralised Orphan - Designation EMEA/OD/032/04 (2004)3001 of 29/07/2004
24/04/2009 Centralised Orphan - Transfer of orphan designation EMEA/OD/032/04/T/01 (2009)3194 of 22/04/2009